We examined the effect of the membranous form of platelet-rich fibrin (PRF) on patients
with medication-related osteonecrosis of the jaw.Our study included patients who underwent
an operation because of second- or third-stage osteonecrosis of the jaw induced by
antiresorptive therapy. The diagnosis of medication-related osteonecrosis of the jaw
was based on the 2009 and 2014 recommendations of the American Association of Oral
and Maxillofacial Surgeons. On the basis of the duration of treatment, we divided
our patients into 2 groups. Patients in the first group (Gr1) underwent traditional
surgical therapy between 2009 and 2014, whereas patients in the second group (Gr2)
underwent PRF membrane-supplemented operations between 2015 and 2017. Outcomes were
assessed based on patient recovery, stage improvement, and relapse rate. The follow-up
period was a minimum of 1 year.Our study included 101 patients: 73 in Gr1 and 28 in
Gr2. The results in Gr2 were significantly better than those in Gr1: recovery (P =
.022), stage improvement (P = .005), and relapse rate (P < .001).In Gr2, significantly
better results were achieved in terms of stage improvement, recovery, and relapse
rate than in Gr1.
